Meeting
2024 ASCO Annual Meeting
Therapeutic implications of phosphoproteomics in molecular cancer diagnostics.
Authors
Annika Schneider
Technical University of Munich (TUM), München, Germany
Annika Schneider , Julia Woortman , Cecilia Bang Jensen , Amirhossein Sakhteman , Maria-Veronica Teleanu , Peter Horak , Simon Kreutzfeldt , Barbara Hutter , Jennifer Huellein , Moritz Resch , Christoph Stange , Chien-Yun Lee , Olaf Witt , David T.W. Jones , Daniel Hübschmann , Stefan M. Pfister , Wilko Weichert , Matthew The , Stefan Froehling , Bernhard Kuster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3068)
DOI
10.1200/JCO.2024.42.16_suppl.3068
Abstract #
3068
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Implementation of an academic-community partnership model for equitable access to precision oncology decision support in rural community cancer centers.
First Author: Anivarya Kumar
Poster
2022 ASCO Quality Care Symposium
Implementation of a virtual, on-demand, molecular tumor board at a large, multi-clinic, community oncology practice.
First Author: Andrew Jacob McKenzie
Poster
2019 ASCO Annual Meeting
Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.
First Author: Pablo Berlanga
Poster
2024 ASCO Annual Meeting
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.
First Author: Andrea Botticelli